A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Completed · Phase 4

Conditions studied: Anti-biotic Resistance

In brief

The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.

Key facts

Study ID

NCT00874887

Run by

Allergan

People needed

66

Starts

2009-03-01

Expected to finish

2009-10-01

Last updated by the study team

2011-12-19

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or Female
• At least 50 years of age
• In good general health

You may not qualify if…

• Any ocular surgery or use of topical antibiotics or antiseptics in either eye within the last 3 months
• Use of topical steroids, or non-steroidal anti inflammatory drugs in either eye within 30 days of Baseline (or anticipated during the study)
• Use of lid scrubs within 7 days of Baseline in either eye (or anticipated use during the study)

Where it is running

• Study site — Minneapolis, Minnesota, United States
• Study site — Saskatoon, Saskatchewan, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.